

Canadian Conference on Dementia

Hot Topics 2024 | Oct 18, 2024 | Virtual



Conference Handbook



<https://events.myconferencesuite.com/CCDHotTopics2024>



Welcome to the Conference.....	4
How to use Zoom Events (Virtual Event Platform)	5
Detailed Program	6
Poster Presentations and Authors	11
Conference Evaluation, Certificate of Attendance, & Board.....	13
Conference Sponsors	14

Get the Most Out of CCD: Hot Topics 2024!

- Visit the **Poster Presentations** at <https://events.myconferencesuite.com/CCDHotTopics2024/page/Posters> to view the work being done by your colleagues, and hear the latest innovations in just 5 minutes during our **New and Notable Presentations** in the afternoon.
- Visit our **Sponsor booth in the Expo area** to interact with their representatives and learn more about them.
- Get your **Certificate of Attendance** and help us plan for next year. A link to the evaluation will be posted in the lobby chat and you will also receive an email from Conference Services with a link to our evaluation survey. Take a few minutes to fill in the evaluation and once you submit the evaluation, you will be able to access your certificate.
- For more information about CCD: Hot Topics 2024, visit <https://events.myconferencesuite.com/CCDHotTopics2024>



Welcome

Canadian Conference on Dementia: Hot Topics 2024

For over 20 years the Canadian Conference on Dementia (CCD) has been dedicated to advancing knowledge on dementia in scientific research and clinical care. This biennial in-person conference has become the preeminent academic national conference attracting more than 700 attendees in recent years. This year we are piloting a virtual meeting to be held on the alternate years to the in-person conference. The virtual format will give us the opportunity to hear from more international speakers and with rapid changes in the field regarding new medications, guidelines, diagnostic tools, and health services best practices. Holding an event every year allows the CCD to provide the most current research.

The program will delve into topics such as: A Report on the New Lancet Commission 2024, AD Blood Biomarkers, Behavioural and Psychological Symptoms of Dementia (BPSD), Quality of Life, Alzheimer's Disease Therapies, MAID, Purpose in Life and Dementia Risk, Inflammatory Biomarkers and Dementia, Digital Markers, MCI, and Tips on Assessment of Function from an OT. We will also hear from the top abstract submissions in the New and Notable session.

Zahinoor Ismail, MD

Chair, Canadian Conference on Dementia




How to use Zoom Events (Virtual Event Platform)

Zoom Events is a platform designed to tie together multiple Zoom meetings into one website interface: webinars, meetings, breakout conference sessions, and sponsor exhibits.

Attendees can chat with individuals or groups in dedicated virtual spaces, and a single virtual booth can host multiple discussions.

Conference participants will join the event with one link. They will land in a virtual lobby and navigate to sessions from there.

The Lobby for the event shows the conference information at a glance with featured and upcoming sessions at the bottom, the Lobby Chat on the right, and the different conference areas/features on the top bar including:



- **Sessions**, where you'll be able to enter the presentations
- **Itinerary**, where you can build your personal agenda for the event
- **Expo**, where you'll find our sponsor booths with their downloadable resources, an area to chat with them, as well as a link to our Poster Presentations
- **Speakers**, where you'll find our speaker information

More information about Zoom Events as an Attendee can be found at <https://support.zoom.us/hc/en-us/articles/4402706205325-Getting-started-as-a-Zoom-Events-attendee>.

If you run into any issues with the platform, please contact conferences@uhn.ca.



detailed program

TIME	SESSION
9:00 - 9:30	Event platform opens to attendees to interact with sponsor exhibits. Posters are available for viewing on the conference website
9:30 - 9:45	Opening Remarks Zahinoor Ismail , MD FRCPC – Conference Chair <i>Clinician Scientist and Professor of Psychiatry, Neurology, Epidemiology, and Pathology at the Hotchkiss Brain Institute and O'Brien Institute for Public Health, University of Calgary</i>
PLENARY SESSION	
9:45 - 10:15	Potential for Reducing Dementia: 2024 Update of the Lancet Commission for Dementia Prevention, Intervention and Care Andrew Sommerlad , MBBS, PhD <i>Associate Professor and Consultant Psychiatrist, Division of Psychiatry, University College London, United Kingdom</i> <p>The 2024 update of the Lancet Commission on dementia provides new hopeful evidence about dementia prevention, intervention, and care. This presentation will summarize new research showing how cognitive and physical reserve develop across the life course and how reducing vascular damage is likely to have contributed to a reduction in age-related dementia incidence. There is also strengthening evidence that tackling many risk factors for dementia that we modelled previously reduces the risk of developing dementia and the session will also present the new compelling evidence that untreated vision loss and high LDL cholesterol are risk factors for dementia.</p>
10:15 - 10:30	Transition to Concurrent Sessions
CONCURRENT SESSIONS <i>Four streams will run concurrently from 10:30 – 12:00. Each stream consists of three 30-minute presentations</i>	
STREAM 1: CLINICAL	
1030 – 11:00	From CSF to Finger Prick Testing for Alzheimer's Disease and Related Neurodegenerative Dementias Henrik Zetterberg , MD, PhD <i>Professor/ Department Head, University of Gothenburg; Clinical Chemist, Sahlgrenska University Hospital, Gothenburg, Sweden</i> <p>This presentation will cover the most exciting recent developments in regards to biofluid-based biomarkers for neurodegenerative dementias.</p>
1100 – 11:30	Prodromal Lewy Body Disease/Dementia Dag Aarsland , MD <i>Professor of Old Age Psychiatry and Director of Centre for Healthy Brain Aging, Institute of Psychiatry, Psychology and Neuroscience, King's College London, England</i> <p>Dementia with Lewy bodies is a common neurodegenerative dementia with a complex and often rapidly developing clinical presentation. The presentation will discuss recent evidence about the earliest clinical and biomarker changes associated with the disease, as well as new proposed staging criteria.</p>
1130 – 12:00	MRI Diagnosis and Markers of Cerebral Small Vessel Disease Marco Duering , MD <i>Professor of Experimental Neurology, LMU Munich, Germany & University of Basel, Switzerland</i> <p>The vascular contribution to dementia is increasingly recognized, particularly in the context of cerebral small vessel disease (cSVD). MRI is the method of choice for diagnosing and monitoring cSVD. This presentation will provide guidance on MRI interpretation in clinical practice and summarize the latest developments towards quantitative imaging biomarkers in cSVD.</p>



TIME	SESSION
STREAM 2: EPIDEMIOLOGY, PUBLIC HEALTH	
1030 – 11:00	Quality of Life and Quality of Care in Dementia Sube Banerjee , MBE, MBBS, MSc, MBA, MD, FRCPsych <i>Pro-Vice Chancellor & Professor of Dementia, University of Nottingham, England</i> <p>In this talk we will consider what constitutes the fundamental goal of treatment and care in dementia. In the era of the first disease modifying medication the focus of trials, regulatory approval and monitoring is increasingly on narrowly defined outcomes such as cognition and function. In the context of the complexity of dementia, we will discuss whether these targets are really what matters to people with dementia and family carers, whether they should be the focus for health services, and the potential implications of taking a narrow view of outcomes in dementia.</p>
11:00 – 11:30	Risk and Protective Factors for Dementia in the Context of Diabetes Mellitus Rachel Whitmer , PhD <i>Professor of Public Health and Neurology</i> <p>In this presentation we will review the association between diabetes and risk of cognitive impairment and will focus on the role of modifiable risk factors. We will review the evidence on glycemic control, macrovascular and microvascular risk factors in both type 1 and type 2 diabetes.</p>
11:30 – 12:00	Brain Health and Public Health, Nation-Wide and Online Zahinoor Ismail , MD FRCPC <i>Clinician Scientist and Professor of Psychiatry, Neurology, Epidemiology, and Pathology at the Hotchkiss Brain Institute and O'Brien Institute for Public Health, University of Calgary</i>
STREAM 3: NEUROBIOLOGY & TECHNOLOGY	
10:30 – 11:00	World-Wide FINGERS: A Global Strategy for Advancing Risk Reduction and Precision Prevention of Dementia Miia Kivipelto , PhD <i>Professor of Clinical Geriatric Epidemiology at the Department of Neurobiology, Care Sciences and Society</i>
11:00 – 11:30	Bedside Assessment Skills for Dementia James Tew , MD <i>Vice President Medical Affairs, UPMC Western Psychiatric Hospital; Associate Chief, UPMC Western Psychiatric Hospital, Inpatient Services; Associate Professor, Department of Psychiatry, University of Pittsburgh School of Medicine, Pennsylvania</i> <p>Clinicians are often pressed for time. They need to develop a set of quick "high yield" bedside assessment skills to capture and document behavioral changes in dementia. This 30-minute presentation from a geriatric psychiatrist will review specific brain-behavioral correlates in dementia, how to elicit them, and document their presence.</p>
11:30 – 12:00	A Roadmap for Digital Biomarkers and Remote Assessment in Dementia Maiya Geddes , MD <i>FRSQ Neurologist Scientist at McGill University, Canada</i> <p>This presentation will provide a framework for the role of digital biomarkers and remote assessment of individuals living with dementia. At the end of the session participants will (1) have an approach to remote cognitive, affective and functional assessment of individuals living with cognitive impairment, and, (2) become familiar with novel strategies for detection and tracking of cognitive and behavioral change using digital biomarkers.</p>

Video recordings of the presentations that we receive consent to share will be made available to registered attendees post event. An email notification with instructions will be provided within a few weeks following the conference.



detailed program

TIME	SESSION
STREAM 4: CAREGIVERS, LONG-TERM CARE, SERVICES	
10:30 - 11:00	<p>Updates on Canadian BPSD Guidelines Dallas Seitz, MD PhD <i>Professor, Department of Psychiatry, Hotchkiss Brain Institute, and O'Brien Institute for Public Health, Cumming School of Medicine, University of Calgary, Co-Chair, Canadian Coalition for Seniors Mental Health, Canada</i></p> <p>Behavioural and psychological symptoms of dementia (BPSD) are common among people living with dementia (PLWD) and can be challenging for PLWD, their care partners and clinicians to manage. This presentation will provide an overview of the CCSMH clinical practice guidelines on the assessment and management of BPSD. Attendees will become familiar with the guideline development process and understand the guideline topics and key recommendations contained in the BPSD guidelines. The Canadian Coalition for Seniors' Mental Health Clinical Practice Guideline for Assessing and Managing Behavioural and Psychological Symptoms of Dementia (BPSD).</p>
11:00 - 11:30	<p>Engaging Persons with Lived Experience to Co-Develop Educational Videos About Vascular Cognitive Impairment Jolene Phelps, PhD <i>Postdoctoral Researcher, University of Victoria, Canada</i> Myrna Norman <i>Patient Partner, Purple Angels, Canada</i> Brian Dompé <i>Edmonton Seniors Coordinating Council Board, United Way of the Alberta Capital Region Re-United Cabinet, Canada</i></p> <p>Increasingly, patients turn to YouTube and other online video websites for health information. To increase the amount of medically accurate content on vascular cognitive impairment (VCI), the CIHR-funded Vascular Training Platform is collaborating with the Engaging Persons with Lived Experience with Dementia group of the Canadian Consortium on Neurodegeneration in Aging to co-develop videos on VCI. Topics will include VCI diagnosis, what to do after a diagnosis, and what health professionals need to know about the lived experience. In this presentation, we will describe methods for co-development, show previews of the videos, and present the findings from an ethics-approved qualitative evaluation led by lived experience researchers.</p>
11:30 - 12:00	<p>Assessing Function in Dementia and Those at Risk - Tips from an Occupational Therapist Lissa Kuzych, OT Reg (Ont) <i>Occupational Therapist, Plum Tree Memory Care; Homecare Therapist, MINT Memory Clinic; Adjunct Clinical Professor, McMaster University, Canada</i></p> <p>Differentiating between MCI and dementia is a common challenge in Primary care and specialty memory clinics. Identification of functional impairment is crucial for an accurate diagnosis of dementia, optimizing home safety and future planning. Assessment of function via caregiver interview, direct patient functional assessment, and home functional assessments will be discussed.</p>
12:00 - 13:30	Lunch, networking with sponsors, poster viewing
CONCURRENT PARALLEL SESSIONS <i>Two sessions will run concurrently from 13:30 – 14:30. Each stream consists of two 30-minute presentations</i>	
PARALLEL 1: CLINICAL SYNDROMES	
1330 – 14:00	<p>Mild Cognitive Impairment in the Era of Alzheimer's Disease Treatments Ron Petersen, MD, PhD <i>Director, Mayo Alzheimer's Disease Research Center and the Mayo Clinic Study of Aging, Minnesota</i></p> <p>Mild cognitive impairment has been available in clinical and research settings for over 20 years. However, in recent years with the approval of disease modifying therapies for Alzheimer's disease, it has taken on increased importance. MCI in clinical diagnostic settings and the use of Alzheimer's Disease biomarkers will be discussed.</p>



TIME	SESSION
PARALLEL 1: CLINICAL SYNDROMES continued	
14:00 - 14:30	<p>Developing a Clinic for Disease-Modifying Therapies in Dementia Vijay Ramanan, MD, PhD <i>Consultant and Assistant Professor, Department of Neurology, Mayo Clinic, Rochester</i></p> <p>With emerging disease-modifying therapeutic options for Alzheimer's and related disorders, there is an imminent need for clinicians to adapt workflows and infrastructure to ensure safe and effective usage. This talk will review key aspects of multidisciplinary care in this new treatment era, with a particular focus on principles important for rational implementation of anti-amyloid infusion therapies for early Alzheimer's Disease.</p>
PARALLEL 2: PSYCHOSOCIAL & LEGAL	
13:30 - 14:00	<p>Loneliness, Purpose in Life, and Subjective Cognitive Decline in Ethno-Racially Diverse Older Adults in the US Yakeel Quiroz, PhD <i>Associate Professor of Psychiatry and Neurology Massachusetts General Hospital, Harvard Medical School, Boston</i></p> <p>Celina Pluim McDowell, MA <i>Clinical Psychology PhD Candidate, Boston University; Predoctoral Neuropsychology Resident, Brown University</i></p> <p>Subjective cognitive decline precedes mild cognitive impairment and dementia, and may be affected by well-being factors including purpose in life and loneliness in older adults. This study examined relationships amongst purpose in life, loneliness, and subjective cognitive decline in an ethnoracially diverse sample including Black, Asian, and Latino adults, groups not well represented in past work, and White adults. Differential predictors of subjective cognitive decline and purpose in life were also identified across these ethnoracial groups.</p>
14:00 - 14:30	<p>MAiD and/or with Dementia: An Update on Legal Developments Daphne Gilbert, BA, LLB, LLM <i>Professor, Faculty of Law, University of Ottawa, Canada</i></p> <p>This presentation will offer an overview of the legal complexities of MAiD for those diagnosed with dementia. It will describe the regime as currently permitted and summarize the new legislation in Quebec that will allow for advance requests for MAiD for those with dementia. It will offer some thoughts/predictions on what may happen in the rest of Canada.</p>
14:30 - 14:45	Break

Video recordings of the presentations that we receive consent to share will be made available to registered attendees post event. An email notification with instructions will be provided within a few weeks following the conference.



detailed program

TIME	SESSION
PLENARY SESSION	
NEW AND NOTABLE - Top 5 Poster Abstracts Five abstracts taken from the call for abstracts will present from 14:45 - 15:15 for 5 minutes each followed by a 5-minute group Q & A	
14:45 - 14:50	Risks and Health-Reinforcing Factors for Cognitive Maintenance in Men and Women: A Secondary Analysis of the Longitudinal SHARE Data Yuliya Bodryzlova , PhD <i>Research Officer, Institut Pinel</i>
14:50 - 14:55	Neuroimaging Markers of Cerebral Small Vessel Disease and Mild Behavioral Impairment Dylan Guan , HBSc, MD/PhD Student <i>Hotchkiss Brain Institute, University of Calgary</i>
14:55 - 15:00	An Index to Quantify Burden of Modifiable Risk for Dementia at the Community-Level in New Brunswick Sandra Magalhaes , BHSc, MSc, PhD (Epidemiology) <i>Research Associate, University of New Brunswick</i>
15:00 - 15:05	A Dementia Registry for Canada: A Community-Driven, Made-in-Ontario Solution Adam Morrison , MSc, CHE <i>Senior Director, Public Policy & Partnerships; Alzheimer Society of Ontario</i>
15:05 - 15:10	Evaluating the Feasibility, Safety, and Efficacy of Transcranial Photobiomodulation (tPBM) for Mild Cognitive Impairment (MCI): Initial Findings from a Pilot Study Neda Rashidi-Ranjbar , MD, PhD <i>Manager of Research Program - Neurodegenerative Disease, Keenan Research Centre for Biomedical Science, Li Ka Shing Knowledge Institute, St. Michael's Hospital</i>
15:10 - 15:15	Q & A
PLENARY SESSION	
15:15 - 15:45	Combination Therapies for Alzheimer's Disease Serge Gauthier , CM, CQ, MD, FRCPC <i>Emeritus Professor in Neurology and Psychiatry; Co-lead of the Dementia Education Program, McGill University</i> There have been some attempts using randomized clinical trials to demonstrate additive benefits when combining drugs with complementary modes of action. Benefits could be symptomatic for cognition, function or behavior, or for disease progression.
15:45 - 16:00	Closing Remarks Zahinoor Ismail , MD FRCPC – Conference Chair <i>Clinician Scientist and Professor of Psychiatry, Neurology, Epidemiology, and Pathology at the Hotchkiss Brain Institute and O'Brien Institute for Public Health, University of Calgary</i>
16:00 - 17:00	Poster Viewing Posters are available for viewing on the conference website at https://events.myconferencesuite.com/CCDHofTopics2024/page/Posters

Video recordings of the presentations that we receive consent to share will be made available to registered attendees post event. An email notification with instructions will be provided within a few weeks following the conference.



#	Poster Title and Authors	Primary Author
1	Implementing robotic pet therapy in continuing care settings: A scoping review of barriers and facilitators <i>B. Fernandes, J. Eng, A. Toohey, B. Lashewicz, M. Charbonneau, J. Holroyd-Leduc</i>	Brooklynn Fernandes
2	Dancing towards better brain health: Virtual GERAS DANCE implementation for dementia care across Canada <i>P. Hewston, A. Papaioannou, C. Marr, A. Dashti, G. Hladysh, E. Coker, J. St Onge, C. Kennedy, G. Ioannidis</i>	Patricia Hewston
3	The Role of a Care Plan Manager in Supporting Family Caregivers in Dementia Care <i>S. Nayak</i>	Smita Nayak
4	Risks and health-reinforcing factors for cognitive maintenance in men and women: a secondary analysis of the longitudinal SHARE data <i>Y. Bodryzlova, G. Moullec</i>	Yuliya Bodryzlova
5	Cognitive Impairments in Older Adults – Clinical Characteristics of Osler's Memory Clinic <i>S. Nadkarni, M. Saldutto, J. Brar, S. Panchadcharadevan, F. Duah, S. Saha</i>	Shailesh Nadkarni
6	Engaging hospitalized patients living with dementia in meaningful moments: An action research approach <i>S. Matarazzo, E. Coker, J. Sue, L. Mersereau, P. Hewston, C. Marr, A. Vehra, A. Papaioannou</i>	Sophia Matarazzo
7	Examining sex differences in health service use before and after diagnosis in a rural and remote memory clinic <i>J. Kosteniuk, B. A. Osman, D. Morgan, C. Karunanayake, M. E. O'Connell, A. Cammer, A. Kir, M. Osman, A. Campbell, T. Levinton, J. Quail</i>	Julie Kosteniuk
8	Surgical trajectory of functional disability and depression in older adults with versus without suspected cognitive impairment: A longitudinal prospective cohort study <i>E. Yan, Y. Alhamdah, N. Butris, P. Kapoor, D. He, F. Chung, C. Tartaglia</i>	Ellene Yan
9	Neuroimaging markers of cerebral small vessel disease and mild behavioral impairment <i>D. Guan, E. E. Smith, A. Ganesh, Z. Ismail</i>	Dylan Guan
10	Sex differences in caregivers' burden and perceptions of neuropsychiatric symptoms in Alzheimer's disease: A cross-sectional study <i>O. Skoda, P. Desmarais, M. Houde, C. Vo-Dignard, D. Rioux</i>	Owen Skoda
11	Identification of predictive factors for neuropsychiatric symptoms across neurodegenerative disorders: Baseline results of a longitudinal study <i>O. Skoda, P. Desmarais, M. Houde, C. Vo-Dignard, D. Rioux</i>	Owen Skoda
12	Comprehensive Clinical and Analytical Validations of Two Novel Plasma pTau217 Immunoassays in a Clinical Diagnostic Laboratory <i>H. Frykman, A. Mammel, A. Mousavi, P. Kumar, M. Encarnacion, K. Hallett, D. Biehl, P. Gil, S. Pflueger, G.-Y. R. Hsiung</i>	Hans Frykman
13	Clinical decision points for two plasma p-tau217 laboratory developed tests in neuropathology confirmed samples <i>H. Frykman, A. Mammel, A. Mousavi, P. Kumar, M. Encarnacion, K. Hallett, I. Mackenzie, V. Hirsch-Reinshagen, D. Biehl, P. Gil, S. Pflueger, G.-Y. R. Hsiung</i>	Hans Frykman
14	The effects of non-modifiable risk factors of Alzheimer's disease (AD) on plasma pTau217 Concentrations <i>H. Frykman, A. Mammel, A. Mousavi, P. Kumar, M. Encarnacion, K. Hallett, D. Biehl, P. Gil, S. Pflueger, G.-Y. R. Hsiung</i>	Hans Frykman
15	Comparison of diagnostic performance of CSF biomarkers with plasma pTau217 concentrations in predicting clinically diagnosed Alzheimer's disease <i>H. Frykman, A. Mammel, A. Mousavi, P. Kumar, M. Encarnacion, K. Hallett, D. Biehl, P. Gil, S. Pflueger, G.-Y. R. Hsiung</i>	Hans Frykman
16	The Performance of Two Plasma tau-217 Immunoassays in Distinguishing Alzheimer's Disease Pathology at Different Stages <i>H. Frykman, A. Mammel, A. Mousavi, P. Kumar, M. Encarnacion, K. Hallett, I. Mackenzie, V. Hirsch-Reinshagen, D. Biehl, P. Gil, S. Pflueger, G.-Y. R. Hsiung</i>	Hans Frykman

*New and Notable Abstract



poster presentations and authors

#	Abstract Population - Senior Focused Care	Representative
17	A Head-to-Head Comparison of Clinical Performance of Two Novel Plasma pTau217 Immunoassays for Detecting Alzheimer's pathology <i>H. Frykman, A. Mammel, A. Mousavi, P. Kumar, M. Encarnacion, K. Hallett, I. Mackenzie, V. Hirsch-Reinshagen, D. Biehl, P. Gil, S. Pflueger, G.-Y. R. Hsiung</i>	Hans Frykman
18	Awareness of Actions to Reduce Dementia Risk Among First Nations People in File Hills Qu'Appelle Tribal Council: A Review of the Brain Health PRO Platform <i>L. Ferrow, N. Akan, J. A. Furlano, N. Anderson, W. Wittich, J. D. Walker, S. Belleville, L. Middleton, A. Froehlich, G. Boehme, C. Ashdoehonk, B. Peigan, N. Jack, R.a McKay, M. Crant, R. Bellegarde</i>	Letebrhan Ferrow
19	Longitudinal associations between vascular risk factors and mild behavioral impairment <i>I. Warring, D. Guan, M. Ghahremani, E. E. Smith, Zahinoor Ismail</i>	Ibadat Warring
20	The interplay of social contact, apathy, and loneliness: Associations with cognitive symptoms in Canadian adults <i>J. F. E. Crockford, D. X. Guan, D. Vellone, E. E. Smith, Z. Ismail</i>	Jasper F.E. Crockford
21	Investigating traumatic brain injury as a moderator in the relationship between cortical thickness and volume and mild behavioral impairment. <i>G. Sidhu, D. Guan, M. Ghahremani, Z. Ismail</i>	Gurshaan Sidhu
22	Association of Mild Behavioural Impairment with plasma inflammatory biomarkers in individuals with Mild Cognitive Impairment <i>S. Azhar, D. Guan, M. Ghahremani, Z. Ismail</i>	Sabika Azhar
23	Barriers to Clinical Care in Frontotemporal Dementia and Related Disorders: Patients and Caregivers' Journey in the Canadian Healthcare System <i>A. Martineau, M. Conant, P. Desmarais</i>	Alexandrine Martineau
24	Canadian Healthcare Providers' Perceptions on Accessibility of Diagnostic Tools and Specialized Resources for Frontotemporal Dementia and Related Disorders <i>A. Martineau, M. Conant, P. Desmarais</i>	Alexandrine Martineau
25	An Education Intervention to Improve Attitudes Towards Dementia and Sense of Competency in Dementia Care Among Nurses in Acute Care Settings: A Mixed Methods Study <i>W. Lam, A. Wang, R. Sears</i>	Winnie Lam
26	Integrating Virtual Reality Reminiscence Therapy into Dementia Care: An Exploratory Study <i>W. Sun, A. Quevedo, S.Elgazzar</i>	Winnie Sun
27	An Index to Quantify Burden of Modifiable Risk for Dementia at the Community-Level in New Brunswick <i>S. Magalhaes, P. Singh, S. Cookson, P. Jarrett, K. Faig, C. McGibbon</i>	Sandra Magalhaes
28	A Dementia Registry for Canada: A community-driven, made-in-Ontario solution <i>A. Morrison, C. Stergiou-Dayment, C. Siu, C. Studzinski</i>	Adam Morrison
29	Unraveling 5 Major Mysteries of Dementia: Insights from the Melanin Theory <i>S. Z. Berg, J. Berg</i>	S.Z. Berg
30	Implementation of novel biomarkers in a real world memory clinic in Canada- Initial findings from the bioMIND study <i>J. Bhangu, M. Borrie, S. Best, K. Van Der Ploeg, A. Patwardhan, J. Wells</i>	Jaspreet Bhangu
31	Evaluating the Feasibility, Safety, and Efficacy of Transcranial Photobiomodulation (tPBM) for Mild Cognitive Impairment (MCI): Initial Findings from a Pilot Study <i>N. W. Churchill, S. J. Graham, D. G. Munoz, T. A. Schweizer, C. E. Fischer, R. Schneider, J. Coull, T. N. Rashidi-Ranjbar, K. Rajji, A. C. Andreadza, L. Lim, L. Fornazzari</i>	Neda Rashidi-Ranjbar
32	Clinical utility of the Montreal Cognitive assessment (MoCA) in Long COVID (PCS) associated brain fog <i>A. G. Juby, C. M.J. Davis</i>	Angela G Juby
33	Identifying endophenotypes of APOE-e4 to unravel clinicopathological heterogeneity and mixed neuropathologies across the Lewy body disease spectrum: current advances and emerging opportunities <i>U. Saeed, M. Masellis</i>	Usman Saeed

*New and Notable Abstract



Conference Evaluation and Certificate of Attendance

Delegate feedback is very important to the committee as it helps to guide the planning process for future conferences.

Please note that when you open up the online evaluation, you must complete the entire survey. If you close out of the survey, it will not save.

The evaluation can be easily accessed on your smart phone/ tablet / laptop via the link below.

Evaluation Link: <https://www.surveymonkey.com/r/2024CCDEval>

After you complete the survey in its entirety, and click DONE, you will be directed to your Certificate of Attendance.

Board and Organizing Committee

Sandra E. Black	Sunnybrook Health Science Centre, University of Toronto
Howard Chertkow	Kimel Family Centre for Brain Health; Anne & Allan Bank Centre for Clinical Research Trials
Serge Gauthier	McGill University
Zahra Goodarzi	Hotchkiss Brain Institute; University of Calgary
Dylan Guan	University of Calgary
Ging-Yeuk Robin Hsiung	University of British Columbia; Consortium of Canadian Centres for Clinical Cognitive Research (C5R)
Zahinoor Ismail - Chair	Hotchkiss Brain Institute; University of Calgary
Mary Pat McAndrew	Krembil Brain Institute, University Health Network
Gary Naglie	University of Toronto; Baycrest Health Sciences
Jacqueline Pettersen	University of British Columbia
Luca F. Pisterzi	Alzheimer Society of Canada; University of Toronto
Saskia Sivananthan	McGill University
Eric Edward Smith	Cognitive Neurosciences Clinic; University of Calgary



CREATING HOPE THROUGH INNOVATION

At Eisai, everything we do is guided by a simple principle: Patients and their families come first. We spend time with them. We listen and we learn about their lives, their desires and their greatest needs. **We call this human health care or hhc**, giving first thoughts to patients and their families and helping increase the benefits health care provides.

Our hhc mission is what drives us to discover innovative solutions and therapies that help address unmet needs within the communities that we seek to serve.

CRÉER L'ESPOIR PAR L'INNOVATION

Chez Eisai, tout ce que nous faisons est guidé par un principe simple : les patients et leurs familles sont notre priorité. Nous leur consacrons du temps. Nous les écoutons et nous nous informons sur leur vie, leurs désirs et leurs besoins les plus importants. **C'est ce que nous appelons le "human health care" ou hhc**, qui consiste à penser d'abord aux patients et à leurs familles et à améliorer les bienfaits que les soins de santé peuvent offrir.

Notre mission hhc est ce qui nous incite à découvrir des solutions et traitements novateurs qui contribuent à combler des besoins médicaux inassouvis pour la communauté que nous désirons servir.

hhc
human health care

TO LEARN MORE, PLEASE VISIT EISAI.CA
POUR EN SAVOIR PLUS, VISITEZ EISAI.CA

Eisai Limited is a Canadian pharmaceutical subsidiary of Tokyo-based Eisai Co. Ltd.
Eisai limitée est une filiale pharmaceutique canadienne de la société Eisai Co., Ltd., basée à Tokyo.

LECA-CA2045

Time is Hiding Something

By the time clinical symptoms of Alzheimer's disease appear, amyloid and tau pathology may have been present for decades.



AMYLOID PATHOLOGY: UP TO 20 YEARS BEFORE CLINICAL SYMPTOMS EMERGE

Accumulation of amyloid beta protein in the form of plaques may be one of the first pathophysiological changes in the brain in Alzheimer's disease.

10-15 YEARS

TAU PATHOLOGY: UP TO 10-15 YEARS BEFORE CLINICAL SYMPTOMS EMERGE

Abnormal accumulation of hyperphosphorylated tau protein leads to the formation of neurofibrillary tangles.



**COMMITTED TO PEOPLE AFFECTED BY ALZHEIMER'S DISEASE.
COMMITTED TO ALZHEIMER'S DISEASE RESEARCH FOR 30 YEARS AND COUNTING.**

The images depicted contain models and are being used for illustrative purposes only.

References: 1. Aisen PS, Cummings J, Jack CR Jr, et al. On the path to 2025: understanding the Alzheimer's disease continuum. *Alzheimers Res & Ther.* 2017; 9(1):1-10. 2. McDade E, Bednar M, Brashear HR, et al. The pathway to secondary prevention of Alzheimer's disease. *Alzheimers Dement (N Y).* 2020;6(1): 1-9. 3. Chen GF, Xu TH, Yan Y, et al. Amyloid beta: structure, biology and structure-based therapeutic development. *Acta Pharmacol Sin.* 2017;38(9):1205-1235. 4. Selkoe DJ, Hardy J. The amyloid hypothesis of Alzheimer's disease at 25 years. *EMBO Mol Med.* 2016;8(6):595-608. 5. Porsteinsson AP, Isaacson RS, Knox S, Sabbagh MN, Rubino I. Diagnosis of early Alzheimer's disease: clinical practice in 2021. *J Prev Alzheimers Dis.* 2021;8(3):371-386. 6. Tosun D, Landau S, Aisen PS, et al. Association between tau deposition and antecedent amyloid- β accumulation rates in normal and early symptomatic individuals. *Brain.* 2017;140(5):1499-1512.



Consider Pr REXULTI[®] for your patients with agitation associated with Alzheimer's dementia (AAD)¹



PrREXULTI[®] is now indicated for the symptomatic management of agitation associated with Alzheimer's dementia (AAD) in patients with aggressive behaviour, unresponsive to non-pharmacological approaches.¹

Please consult the Product Monograph at www.rexultimonograph.ca for important information relating to clinical use, warnings and precautions, adverse reactions, drug interactions, and dosing information which have not been discussed in this piece. The Product Monograph is also available by calling us at **1-877-341-9245**.

Thank you to our Sponsors

Platinum Sponsors



Gold Sponsor

